Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SPPI

Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis

Spectrum Pharmaceuticals logo

About Spectrum Pharmaceuticals Stock (NASDAQ:SPPI)

Advanced Chart

Key Stats

Today's Range
$1.03
$1.03
50-Day Range
$0.94
$1.03
52-Week Range
$0.32
$1.57
Volume
N/A
Average Volume
1.93 million shs
Market Capitalization
$211.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Receive SPPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPPI Stock News Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
See More Headlines

SPPI Stock Analysis - Frequently Asked Questions

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.07.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spectrum Pharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Toast (TOST), Ginkgo Bioworks (DNA) and NOVONIX (NVNXF).

Company Calendar

Last Earnings
11/10/2021
Today
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SPPI
Employees
86
Year Founded
2002

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,400,000.00
Pretax Margin
-263.04%

Debt

Sales & Book Value

Annual Sales
$10.11 million
Price / Cash Flow
N/A
Book Value
$0.15 per share
Price / Book
6.87

Miscellaneous

Free Float
199,704,000
Market Cap
$211.41 million
Optionable
Optionable
Beta
2.15

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:SPPI) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners